Unveiling 6 Analyst Insights On Harmony Biosciences
Portfolio Pulse from Benzinga Insights
In the past three months, six analysts have rated Harmony Biosciences (NASDAQ:HRMY), with all ratings being bullish. The average 12-month price target remains at $52.0, with a high of $56.00 and a low of $48.00. Analysts from UBS, Needham, and Citigroup have maintained or announced 'Buy' ratings. Harmony Biosciences shows a positive revenue trend with a 28.76% growth rate, a net margin of 6.71%, and a conservative debt-to-equity ratio of 0.35.
September 10, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences has received six bullish ratings from analysts, with a stable average price target of $52.0. The company's financials show a positive revenue trend and strong net margin, though ROE is below industry averages.
The unanimous bullish ratings from analysts and stable price target suggest positive sentiment towards HRMY. The company's strong revenue growth and net margin further support a positive outlook, despite a lower ROE.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100